SBIR/STTR Research Award
Novel Antifungals by Engineering the AbA NRPS gene
Award amount
$162,982Program and phase
SBIR · Phase IAward year
2004Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AUREOGEN, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- NETHCTLPJSR4
- Solicitation number
- PHS2004-2
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): There is an immediate need for efficient, novel antifungal drugs. The fungus Aureobasidium pullulans produces a cyclic peptide know as Aureobasidin A (AbA) which is a very potent, fungicidal drug that is currently bar
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Antifungals by Engineering the AbA NRPS gene
- Generation of novel drugs against drug resistant bacteria through engineering of
- Generation of novel HCV drugs through engineereing of the cssA gene
- A Bacitracin derivative for systemic use
- Novel Antifungals by Engineering the AbA NRPS gene
Research funding history
6 SBIR/STTR records share this UEI (2004–2011). Reported award amounts total $3,891,025. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services